Seeking men and women whose locally-advanced stage III Non-small Cell Lung Cancer (NSCLC) can not be treated with surgery for a study of adding an investigational drug to the standard chemoradiation therapy.
Participants in this study will either get the investigational drug in combination with the standard therapy or the standard therapy. Over a period of 14 months the experimental drug combination will be given once every 3 weeks and the standard drug combination will be given every 2 weeks. All participants will get external beam radiation therapy 5 times a week for 6 weeks.
What we're hoping for
We are comparing whether a drug combination including an investigational drug to the standard drug combination chemoradiation therapy improves outcomes for people with stage III non-small cell lung cancer that can't be treated with surgery.
ClinicalTrials.gov Identifier: NCT05298423